Results 131 to 140 of about 503,079 (239)

Hypokalemic Periodic Paralysis Syndrome. [PDF]

Cureus
Govil D, Desai S, Singh K, Soueidan A.
europepmc   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau, Pierre Karam, Anne Forestier, Bertrand Degos   +3 more
wiley   +1 more source

Thyrotoxicosis presenting with periodic paralysis in a young male: a case report. [PDF]

Ann Med Surg (Lond)
Sankhi MN, Samadarshi S, Bansal N, Mohan L, Kunwor B, Chhetri ST.   +5 more
europepmc   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source

Late-Onset Episodic Weakness With Hyperkalemia Suggestive of Hyperkalemic Periodic Paralysis. [PDF]

Cureus
Pandey HK, Sivakumar K, Gudenkauf KJ, Kadakia R.   +3 more
europepmc   +1 more source

Living with the Unknown: Intolerance of Uncertainty in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is marked by pervasive uncertainty due to fluctuating motor and non‐motor symptoms, variable treatment response, and an unpredictable clinical course. Intolerance of uncertainty (IU), a tendency to perceive ambiguity as threatening and respond with worry, avoidance, or decisional paralysis, may be ...
Bradley McDaniels, Gregory M. Pontone, Kuhan Pushparatnam, Indu Subramanian   +3 more
wiley   +1 more source

Thyrotoxic Hypokalemic Periodic Paralysis in Colombia: From a Single Case to a Review of the National Experience. [PDF]

Diseases
Nati-Castillo HA, Abreu Lomba A, Urrea Ospina JD, Saavedra-Torres JS, Lozano Ciro S, Vela Paz J, Alvis Linero NJ, Izquierdo-Condoy JS.   +7 more
europepmc   +1 more source

Predictors for Successful Non‐Invasive Ventilation in Patients With Neuralgic Amyotrophy and Phrenic Nerve Involvement

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Phrenic nerve involvement in neuralgic amyotrophy (NA) may cause diaphragm paresis and respiratory impairment, for which chronic non‐invasive ventilation (NIV) may be beneficial. Data on treatment success and predictors are lacking.
A. B. Hendrikx, R. T. Sprooten, B. A. Vosse, S. C. Steijns, S. M. van Kuijk, J. G. Hoeijmakers, F. M. Franssen   +6 more
wiley   +1 more source

A case and literature review of hypokalemic periodic paralysis associated with heavy cola consumption. [PDF]

Front Nutr
Chen W, Pang Y, Qiu J.
europepmc   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source